Area:
Physiology Biology, Cell Biology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Eric S. Ubil is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2020 — 2021 |
Ubil, Eric S |
K22Activity Code Description: To provide support to outstanding newly trained basic or clinical investigators to develop their independent research skills through a two phase program; an initial period involving and intramural appointment at the NIH and a final period of support at an extramural institution. The award is intended to facilitate the establishment of a record of independent research by the investigator in order to sustain or promote a successful research career. |
Enhanced Immunotherapy by Targeting the Pros1:Macrophage Mer Axis @ University of Alabama At Birmingham
PROJECT SUMMARY/ABSTRACT Tumors can utilize mechanisms of normal physiological immune regulation to suppress the tumor-specific immune response. Targeted immunotherapies directed against immune checkpoints, like PD-1/PD-L1 and CTLA4, have improved patient outcomes but are only effective in a subset of cancers. The durable responses of some patients, resulting from checkpoint-targeted therapy, has sparked great interest in identifying and targeting other innate and adaptive immune checkpoints. Recent studies have identified the Tyro3/Axl/Mer (TAM) family of receptor tyrosine kinases as a novel innate immune checkpoint. Ubil et al. (JCI, 2018) show that tumors secrete Pros1, a Tyro3/Mer ligand, which suppresses the pro-inflammatory M1 response of host macrophages. Pros1 binding induces the recruitment of p38 and PTP1b to Mer, preventing nuclear translocation of p38 and subsequent expression of M1 associated genes. Genetic deletion of macrophage Mer or PTP1b restores M1 polarization in the presence of Pros1. By targeting Pros1:macrophage Mer signaling it may be possible to enhance cancer immunotherapy. To better understand and prevent Mer mediated immune suppression the following specific aims are proposed: 1) Determine the roles of Mer kinase activity and adapter protein recruitment in M1 suppression, 2) Identify the basis for variable immune suppression by Pros1 secreting tumors and 3) Ascertain whether PTP1b inhibition as mono- or combination therapy can increase intra-tumoral immune infiltrate and improve survival. To establish the importance of Mer kinase activity, CRISPR will be used to genetically ablate the Mer ATP binding site and RNAseq used to monitor global transcriptional changes during Pros1 induced M1 suppression. Bioinformatics analysis will identify key pathways affected by Mer kinase, which will be validated biochemically. Immunoprecipitation and proteomic analysis will be used to determine the importance of Pros1-induced dynamic adapter protein recruitment and novel protein:protein associations. Subtle genetic alterations can lead to reduced Pros1 protein activity. Changes in tumor Pros1 sequence will be correlated with ability to suppress M1 polarization and a predictive model constructed to identify which tumors will be susceptible to Pros1:Mer targeted therapy. Efficacy of pharmacological PTP1b inhibition (mono- and combination therapy) to increase tumor immune infiltrate and survival will be determined in primary and metastatic tumor models. Together, the proposed study may identify novel therapeutic targets to prevent Pros1:Mer mediated immune suppression, yield predictive criteria as to which patients may benefit from Pros1:Mer targeted therapy and whether pharmacological PTP1b inhibition is a viable strategy to improve the immune response to cancer.
|
0.942 |